<div style="margin-bottom: 12px;">
    <a href="https://www.fiercepharma.com/pharma/eyepoint-dinged-fda-warning-letter-over-manufacturing-shortfalls-tied-eye-implant" style="color: black; font-weight: bold;">EyePoint dinged with FDA warning letter over manufacturing shortfalls tied to eye implant</a><br/>
    <span style="margin-bottom: 8px">After hitting a regulatory snare with its lead drug candidate earlier this year, ophthalmology specialist EyePoint Pharmaceuticals has run up against another spot of trouble with the FDA.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.spokesman.com/stories/2024/aug/27/fda-approves-neffy-a-nasal-spray-alternative-to-an/" style="color: black; font-weight: bold;">FDA approves Neffy, a nasal spray alternative to an EpiPen that does not need a needle to stop an allergic reaction</a><br/>
    <span style="margin-bottom: 8px">Those at risk of a severe allergic reaction always have handy an EpiPen just in case. But soon their life might be saved by a spray in the nose rather than a needle to the thigh. Last week the FDA approved Neffy, an epinephrine nasal spray, for use in emergency allergic reactions for kids and adults.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.msn.com/en-us/health/other/fda-clears-first-automated-device-to-deliver-insulin-to-people-with-type-2-diabetes/ar-AA1pxasB" style="color: black; font-weight: bold;">FDA Clears First Automated Device to Deliver Insulin to People With Type 2 Diabetes</a><br/>
    <span style="margin-bottom: 8px">The U.S. Food and Drug Administration on Monday approved the expanded use of an automated insulin pump system to include those with type 2 diabetes. It's the first such system for use by people with the more prevalent type 2 form of the disease.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.curetoday.com/view/gsk-227-gets-fda-breakthrough-therapy-designation-for-es-sclc" style="color: black; font-weight: bold;">GSK’227 Gets FDA Breakthrough Therapy Designation for ES-SCLC</a><br/>
    <span style="margin-bottom: 8px">The Food and Drug Administration (FDA) has granted breakthrough therapy designation to the antibody-drug conjugate GSK5764227 (GSK’227) for the treatment of relapsed or refractory extensive-stage small cell lung cancer.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.medpagetoday.com/infectiousdisease/covid19/111681" style="color: black; font-weight: bold;">FDA Could Soon Limit Use of Only Drug for COVID Prevention,FDA Could Soon Limit Use of Only Drug for COVID Prevention"</a><br/>
    <span style="margin-bottom: 8px">Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%, the FDA announced on Monday.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.marketwatch.com/story/illumina-gets-fda-approval-for-cancer-biomarker-test-14e0424a" style="color: black; font-weight: bold;">Illumina Gets FDA Approval for Cancer Biomarker Test</a><br/>
    <span style="margin-bottom: 8px">Illumina received Food and Drug Administration approval for its TruSight Oncology Comprehensive biomarker test for cancer and its two companion diagnostic uses.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.wral.com/story/fda-gives-patients-hope-after-approving-brain-cancer-drug-with-duke-ties/21596406/" style="color: black; font-weight: bold;">FDA gives patients hope after approving brain cancer drug with Duke ties</a><br/>
    <span style="margin-bottom: 8px">Patients with low-grade gliomas now have a new treatment option for the first time in decades. The FDA approved vorasidenib earlier this month for adult and pediatric patients 12 and older with Grade2 astrocytoma or oligodendroglioma.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://pharmaphorum.com/news/astellas-hit-us-patent-verdict-incontinence-drug" style="color: black; font-weight: bold;">Astellas hit by US patent verdict for incontinence drug</a><br/>
    <span style="margin-bottom: 8px">A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockbuster therapy from generic competition.</span>
</div>
